Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. [electronic resource]
- Leukemia 03 2018
- 729-735 p. digital
Publication Type: Journal Article
1476-5551
10.1038/leu.2017.286 doi
Adult Aged Aged, 80 and over Biomarkers Combined Modality Therapy Female Humans Immunoglobulin Light Chains--blood Immunoglobulin Light-chain Amyloidosis--blood Male Middle Aged Organ Specificity Phenotype Prognosis Proportional Hazards Models Symptom Assessment Treatment Outcome